Balance Sheet
Liabilities and Shareholders Equity
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Total Non-Current Liabilities (2017 - 2024)

KalVista Pharmaceuticals' Total Non-Current Liabilities history spans 9 years, with the latest figure at $126.0 million for Q4 2024.

  • For Q4 2024, Total Non-Current Liabilities changed N/A year-over-year to $126.0 million; the TTM value through Dec 2024 reached $126.0 million, changed N/A, while the annual FY2024 figure was $6.0 million, N/A changed from the prior year.
  • Total Non-Current Liabilities for Q4 2024 was $126.0 million at KalVista Pharmaceuticals, up from $4.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $126.0 million in Q4 2024 and bottomed at $932000.0 in Q4 2020.
  • The 4-year median for Total Non-Current Liabilities is $4.8 million (2024), against an average of $14.1 million.
  • The largest YoY upside for Total Non-Current Liabilities was 6.55% in 2020 against a maximum downside of 75.52% in 2020.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $932000.0 in 2020, then rose by 20.49% to $1.1 million in 2021, then soared by 482.9% to $6.5 million in 2023, then soared by 1825.25% to $126.0 million in 2024.
  • Per Business Quant, the three most recent readings for KALV's Total Non-Current Liabilities are $126.0 million (Q4 2024), $4.7 million (Q4 2024), and $5.0 million (Q3 2024).